Form 6-K BioLineRx Ltd. For: Dec 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Roth Capital Lifts PT on BioLineRx (BLRX) to $10.50 Following Investor Day; BL-8040 in AML Remains Promising
December 15, 2014 8:27 AM ESTRoth Capital raises its price target on BioLineRx (Nasdaq: BLRX) from $8 up to $10.50 while maintaining a Buy rating following the company's recent investor day.
Analyst Joseph Pantginis noted the following points following BioLineRx's investor event:
We are providing further views on BioLineRx' investor event, including positive KOL views on the prospects of BL-8040 in AML. Based on the data at ASH and the expanding profile for BL-8040, we are increasing our price target to $10.50 from... More
Roth Keeps BioLineRx (BLRX) at 'Buy'; Sees BL-8040 Plan Progressing Nicely Following Recent Update
December 12, 2014 3:33 PM ESTRoth Capital affirms BioLineRx Ltd. (Nasdaq: BLRX) at Buy with a price target of $8 following the company's investor meeting this week and presented its multi-year plan for development of its CXCR4 antagonist, BL-8040.
Analyst Joseph Pantginis said, We believe BLRX is proceeding wisely with... More
